An ESMO roadmap for implementing molecular tumour boards
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice
Are we close to personalise immunotherapy?
According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher, tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field
Drug Rediscovery Protocol-like Clinical Trials facilitate access to precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types
Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
Translational research: from bytes to bedside
According to Prof. Serena Nik-Zainal, 2024 ESMO Translational Research Awardee it is important to change the mindset of the cancer community to embrace all the information available through genome research
Tumour-agnostic oncology – time has come to re-think clinical research
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
When to perform next-generation sequencing test in patients with cancer? ESMO updates its recommendations
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
New insights into the evolutionary pattern of breast cancer
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Cancer Research
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed